2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗

2019-03-01 亚洲心血管专家小组(统称) Intern Med J. 2019 Mar;49 Suppl 1:5-8.

目前,大规模试验的新证据和指南的更新证实了急性冠脉综合征(ACS)患者延长双联抗血小板治疗的风险和获益。本文主要针对亚洲急性冠脉综合征患者双抗治疗的延长的几个危险因素提出了相应的建议。

中文标题:

2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗

英文标题:

Extended dual antiplatelet therapy for Asian patients with acute coronary syndrome: expert recommendations.

发布日期:

2019-03-01

简要介绍:

目前,大规模试验的新证据和指南的更新证实了急性冠脉综合征(ACS)患者延长双联抗血小板治疗的风险和获益。本文主要针对亚洲急性冠脉综合征患者双抗治疗的延长的几个危险因素提出了相应的建议。 

拓展指南:急性冠脉综合征相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗)] GetToolGuiderByIdResponse(projectId=1, id=a1be41c001e13236, title=2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗, enTitle=Extended dual antiplatelet therapy for Asian patients with acute coronary syndrome: expert recommendations., guiderFrom=Intern Med J. 2019 Mar;49 Suppl 1:5-8., authorId=null, author=, summary=目前,大规模试验的新证据和指南的更新证实了急性冠脉综合征(ACS)患者延长双联抗血小板治疗的风险和获益。本文主要针对亚洲急性冠脉综合征患者双抗治疗的延长的几个危险因素提出了相应的建议。 , cover=, journalId=null, articlesId=null, associationId=1580, associationName=亚洲心血管专家小组(统称), associationIntro= , copyright=0, guiderPublishedTime=Fri Mar 01 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>目前,大规模试验的新证据和指南的更新证实了急性冠脉综合征(ACS)患者延长双联抗血小板治疗的风险和获益。本文主要针对亚洲急性冠脉综合征患者双抗治疗的延长的几个危险因素提出了相应的建议。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>急性冠脉综合征</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=c35121c00162226a" title="2018 欧洲联合共识声明:房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理" target=_blank>2018 欧洲联合共识声明:房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=b99411c00161866d" title="2018 台湾非ST段抬高型急性冠脉综合征的管理指南" target=_blank>2018 台湾非ST段抬高型急性冠脉综合征的管理指南</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=c0d9b1c00160ae19" title="血小板功能检测在急性冠脉综合征患者抗血小板治疗中的应用专家共识" target=_blank>血小板功能检测在急性冠脉综合征患者抗血小板治疗中的应用专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=73b2e1c00159894a" title="2018 台湾专家共识:急性冠脉综合征抗血小板治疗不良反应管理" target=_blank>2018 台湾专家共识:急性冠脉综合征抗血小板治疗不良反应管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=44b8c1c001a690a0" title="非ST段抬高型急性冠脉综合征诊断和治疗指南(2016)" target=_blank>非ST段抬高型急性冠脉综合征诊断和治疗指南(2016)</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E6%80%A5%E6%80%A7%E5%86%A0%E8%84%89%E7%BB%BC%E5%90%88%E5%BE%81" target=_blank>有关急性冠脉综合征更多指南</a></ul>, tagList=[TagDto(tagId=360, tagName=急性冠脉综合征), TagDto(tagId=14625, tagName=双抗治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10535, appHits=480, showAppHits=0, pcHits=8167, showPcHits=2917, likes=166, shares=62, comments=3, approvalStatus=1, publishedTime=Fri Mar 15 00:00:46 CST 2019, publishedTimeString=2019-03-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Mar 15 00:00:46 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 22:18:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗)])
2019 专家建议:延长亚洲急性冠脉综合征患者双抗治疗
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=917881, encodeId=bc7291e881b3, content=了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 18 22:06:12 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897434, encodeId=991e89e434b9, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:13 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364229, encodeId=38b7364229d7, content=了解一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Apr 06 18:37:50 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2021-01-18 wxl882001

    了解

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=917881, encodeId=bc7291e881b3, content=了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 18 22:06:12 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897434, encodeId=991e89e434b9, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:13 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364229, encodeId=38b7364229d7, content=了解一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Apr 06 18:37:50 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2020-11-06 1477308bm10(暂无昵称)

    学习一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=917881, encodeId=bc7291e881b3, content=了解, beContent=null, objectType=guider, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Jan 18 22:06:12 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=897434, encodeId=991e89e434b9, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201109/c4a2f0cf055e4bc8bb3970902a633d4c/150e8482ab7446959f44f9c8dd6e022c.jpg, createdBy=19d75217845, createdName=1477308bm10(暂无昵称), createdTime=Fri Nov 06 22:51:13 CST 2020, time=2020-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364229, encodeId=38b7364229d7, content=了解一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Apr 06 18:37:50 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 wxl882001

    了解一下

    0